Table 3 Overview of AEs
AE Data are n (%) unless stated otherwise | Belumosudil 200 mg once daily (N = 30) |
|---|---|
Any AEs | 29 (96.7%) |
Grade ≥ 3 AEs | 11 (36.7%) |
Drug-related AEs | 19 (63.3%) |
SAEs | 11 (36.7%) |
Drug-related SAEs | 4 (13.3%) |
AEs leading to dose reduction | 1 (3.3%) |
AEs leading to dose interruption | 2 (6.7%) |
AEs leading to treatment discontinuation | 5 (16.7%) |
AEs leading to death | 4 (13.3%) |
All-grade TEAEs (≥ 10% of patients) | |
Respiratory tract infectiona | 14 (46.7%) |
Sinus tachycardia | 11 (36.7%) |
Pneumonia | 7 (23.3%) |
Hypoproteinemiab | 6 (20.0%) |
Hyperuricemia | 5 (16.7%) |
Liver injury | 5 (16.7%) |
Alanine aminotransferase increased | 3 (10.0%) |
Blood creatinine increased | 3 (10.0%) |
Blood glucose increased | 3 (10.0%) |
Hypertension | 3 (10.0%) |
Nausea | 3 (10.0%) |
Vomiting | 3 (10.0%) |
Grade ≥ 3 TEAEs (≥ 5% of patients) | |
Pneumonia | 5 (16.7%) |